| PRECLINICAL | evidence | Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. | Tirzepatide | — | 2026-07-22 |
| PRECLINICAL | evidence | Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024. | Tirzepatide | — | 2026-07-22 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans. | Tirzepatide | — | 2026-07-21 |
| PRECLINICAL | evidence | Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-07-21 |
| PRECLINICAL | evidence | Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. | Tirzepatide | Glycemic control | 2026-07-21 |
| PRECLINICAL | evidence | Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - an overview of current clinical practice and future perspectives. | Tirzepatide | — | 2026-07-21 |
| PRECLINICAL | evidence | Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk. | Tirzepatide | — | 2026-07-20 |
| PRECLINICAL | evidence | Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. | Tirzepatide | — | 2026-07-17 |
| PRECLINICAL | evidence | Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide. | Tirzepatide | — | 2026-07-17 |
| PRECLINICAL | evidence | Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study. | Tirzepatide | Weight & fat loss | 2026-07-16 |
| PRECLINICAL | evidence | Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study. | Tirzepatide | — | 2026-07-16 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder. | Tirzepatide | Glycemic control | 2026-07-15 |
| PRECLINICAL | evidence | Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists. | Tirzepatide | — | 2026-07-15 |
| PRECLINICAL | evidence | Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs. | Tirzepatide | — | 2026-07-14 |
| PRECLINICAL | evidence | Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-07-14 |
| PRECLINICAL | evidence | Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes. | Tirzepatide | — | 2026-07-14 |
| PRECLINICAL | evidence | Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters. | Tirzepatide | — | 2026-07-14 |
| PRECLINICAL | evidence | Medical Treatments for Obesity: What Does the Future Have in Store? | Tirzepatide | — | 2026-07-14 |
| PRECLINICAL | evidence | Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis. | Tirzepatide | — | 2026-07-13 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists and Fertility: What Is Known So Far? | Tirzepatide | — | 2026-07-13 |
| PRECLINICAL | evidence | Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database. | Tirzepatide | — | 2026-07-13 |
| PRECLINICAL | evidence | Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial. | Tirzepatide | — | 2026-07-11 |
| PRECLINICAL | evidence | Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes. | Tirzepatide | — | 2026-07-11 |
| PRECLINICAL | evidence | Pharmacologic Treatment for Obstructive Sleep Apnea in Older Adults. | Tirzepatide | — | 2026-07-11 |
| PRECLINICAL | evidence | The Periprocedural Safety of Continued GLP-1 Receptor Agonist Prior to Cardiac Catheterization. | Tirzepatide | — | 2026-07-11 |
| PRECLINICAL | evidence | Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X). | Mounjaro | — | 2026-07-10 |
| PRECLINICAL | evidence | Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults. | Tirzepatide | — | 2026-07-09 |
| PRECLINICAL | evidence | Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025. | Zepbound | — | 2026-07-09 |
| PRECLINICAL | evidence | Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients. | Tirzepatide | — | 2026-07-09 |
| PRECLINICAL | evidence | Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study. | Tirzepatide | — | 2026-07-09 |
| PRECLINICAL | evidence | Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management? | Tirzepatide | — | 2026-07-09 |
| PRECLINICAL | evidence | Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. | Tirzepatide | Weight & fat loss | 2026-07-08 |
| PRECLINICAL | evidence | Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists. | Tirzepatide | — | 2026-07-08 |
| PRECLINICAL | evidence | Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease. | Tirzepatide | — | 2026-07-08 |
| PRECLINICAL | evidence | National trends in prescription drug expenditures and projections for 2026. | Tirzepatide | — | 2026-07-08 |
| PRECLINICAL | evidence | Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis. | Tirzepatide | — | 2026-07-07 |
| PRECLINICAL | evidence | Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses. | Tirzepatide | — | 2026-07-07 |
| PRECLINICAL | evidence | GLP-1 medications: use and interest in a representative survey of Finns. | Mounjaro | — | 2026-07-07 |
| PRECLINICAL | evidence | Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial. | Tirzepatide | — | 2026-07-07 |
| PRECLINICAL | evidence | A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice. | Tirzepatide | — | 2026-07-06 |
| PRECLINICAL | evidence | Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series. | Tirzepatide | — | 2026-07-06 |
| PRECLINICAL | evidence | Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-07-06 |
| PRECLINICAL | evidence | Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers. | Tirzepatide | — | 2026-07-06 |
| PRECLINICAL | evidence | Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis. | Tirzepatide | — | 2026-07-04 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in pediatric obesity. | Tirzepatide | — | 2026-07-04 |
| PRECLINICAL | evidence | Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists. | Tirzepatide | — | 2026-07-03 |
| PRECLINICAL | evidence | Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study. | Tirzepatide | — | 2026-07-03 |
| PRECLINICAL | evidence | Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology. | Tirzepatide | — | 2026-07-03 |
| PRECLINICAL | evidence | GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease. | Tirzepatide | — | 2026-07-03 |
| PRECLINICAL | evidence | Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand. | Tirzepatide | Weight & fat loss | 2026-07-02 |